Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

About this update from Shanghai Junshi Biosciences Co., Ltd. Class A

[{"type":"image","alt":"Junshi Biosciences","displaySize":"","headline":null,"caption":"Junshi Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4euD1KvxSTvPpofaq76LRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc","width":150,"height":56}},"lazy":false},{"type":"text","content":"SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates.","length":357,"tagName":"p"},{"type":"text","content":"FINANCIAL HIGHLIGHTS","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of Junshi Biosciences was approximately RMB1,948 million in 2024, representing an increase of approximately 30% compared to 2023, which was mainly due to the increase in revenue from pharmaceutical products, in particular: the domestic sales revenue of our core product, toripalimab, was approximately RMB1,501 million, representing an increase of approximately 66% compared to 2023.","length":397,"tagName":"p"}]},{"val":[{"type":"text","content":"Total research and development (“R&D”) expenses of the company were approximately RMB1,275 million in 2024, representing a decrease of approximately 34% compared to 2023. The decrease in R&D expenses was mainly due to the company’s cost control policy and efforts to optimize resource allocation and focus on R&D pipelines with greater potential. In addition, a number of clinical trials of our core product, toripalimab, successively met the primary endpoints, which also contributed to the natural decline of R&D expenditure.","length":543,"tagName":"p"}]},{"val":[{"type":"text","content":"Loss attributable to owners of the company decreased to RMB1,282 million in 2024, representing a decrease of approximately RMB999 million or approximately 44% compared to 2023.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"As of the ...

More updates from Shanghai Junshi Biosciences Co., Ltd. Class A